Geissler E K, Scherer M N, Graeb C
University of South Alabama, Department of Medical Technology, Mobile 36604-3273, USA.
Transpl Int. 1998;11 Suppl 1:S357-60. doi: 10.1007/s001470050497.
Previous studies suggest liver transplants can protect other transplanted organs. This effect may be mediated by hepatocytes secreting large amounts of soluble MHC class I antigen. Here our aim was to determine whether immunologic priming by membrane-bound alloantigen could be inhibited by allospecific antigen produced in a secreted form. Cultured Lewis (RT1.A1) hepatocytes were transfected with plasmids encoding either a membrane-bound or secreted form of the alloantigen, RT1.Aa. Cytotoxic T-lymphocyte (CTL) precursor assays were performed on Lewis splenocytes cultured with transfected hepatocytes, or hepatocytes were injected into the portal vein of prospective Lewis recipients of an ACI (RT1.Aa) liver allograft. Results showed CTL priming by membrane-bound RT1.Aa was inhibited in vitro by soluble RT1.Aa. Similarly, acceleration of ACI allograft rejection induced by membrane-bound antigen was abrogated following co-injection of hepatocytes secreting donor alloantigen. In conclusion, production of soluble donor alloantigen by liver transplants may provide protection against the alloimmune response.
先前的研究表明,肝移植可以保护其他移植器官。这种效应可能是由肝细胞分泌大量可溶性MHC I类抗原介导的。在这里,我们的目的是确定分泌形式产生的同种特异性抗原是否能够抑制膜结合同种异体抗原引发的免疫致敏。用编码膜结合或分泌形式同种异体抗原RT1.Aa的质粒转染培养的Lewis(RT1.A1)肝细胞。对与转染肝细胞共培养的Lewis脾细胞进行细胞毒性T淋巴细胞(CTL)前体细胞分析,或将肝细胞注入接受ACI(RT1.Aa)肝移植的Lewis受体的门静脉。结果显示,可溶性RT1.Aa在体外抑制了膜结合RT1.Aa引发的CTL致敏。同样,在共同注射分泌供体同种异体抗原的肝细胞后,由膜结合抗原诱导的ACI同种异体移植排斥反应加速现象被消除。总之,肝移植产生可溶性供体同种异体抗原可能提供针对同种免疫反应的保护作用。